Molecular and Cellular Basis of Misfolded Proteins in Neurodegenerative Diseases
International Clinical Neuroscience Journal,
Vol. 9 (2022),
10 January 2022
,
Page e32
Abstract
Neurodegeneration is characterized by a progressive loss of nerve structure and function which lead to cognitive impairment such as dementia. Neurodegenerative diseases (NDs) are partially caused by neuronal cell death and glial homeostasis. NDs such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) can develop with aging. As well, in Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), genetic mutations can affect CNS cell function. NDs occur through important processes including, protein misfolding and aggregation of misfolded proteins. These processes cause neurofibrillary tangles and plaques that result in neuronal cytotoxicity. Here, our intention is to shed light on some of the key roles of protein misfolding and aggregation in NDs. This review focuses specifically on understanding the molecular and cell-based mechanisms of protein misfolding and aggregation involved in the development of NDs.
- Neurodegenerative Diseases, Protein Aggregation, Mutation, Posttranslational Modifications
How to Cite
References
Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10 Suppl:S10-7. doi: 10.1038/nm1066.
Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4(1):49- 60. doi: 10.1038/nrn1007.
Zare Mehrjerdi F, Niknazar S, Yadegari M, Akbari FA, Pirmoradi Z, Khaksari M. Carvacrol reduces hippocampal cell death and improves learning and memory deficits following lead-induced neurotoxicity via antioxidant activity. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(7):1229-37. doi: 10.1007/s00210-020-01866-6.
Dunker AK, Silman I, Uversky VN, Sussman JL. Function and structure of inherently disordered proteins. Curr Opin Struct Biol. 2008;18(6):756-64. doi: 10.1016/j.sbi.2008.10.002.
Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21(10):1332-40. doi: 10.1038/s41593-018- 0235-9.
Sorg C, Grothe MJ. The complex link between amyloid and neuronal dysfunction in Alzheimer’s disease. Brain. 2015;138(Pt 12):3472-5. doi: 10.1093/brain/awv302.
Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM. Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci U S A. 1998;95(8):4224-8. doi: 10.1073/pnas.95.8.4224.
Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem. 2009;78:477-513. doi: 10.1146/annurev. biochem.78.081507.101607.
Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164-73. doi: 10.1002/ana.10795.
Gorman AM. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med. 2008;12(6a):2263-80. doi: 10.1111/j.1582- 4934.2008.00402.x.
Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358-72. doi: 10.1038/nrn3880.
Decker H, Lo KY, Unger SM, Ferreira ST, Silverman MA. Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. J Neurosci. 2010;30(27):9166- 71. doi: 10.1523/jneurosci.1074-10.2010.
Takalo M, Salminen A, Soininen H, Hiltunen M, Haapasalo A. Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am J Neurodegener Dis. 2013;2(1):1-14.
Goedert M, Ghetti B, Spillantini MG. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(2):a006254. doi: 10.1101/cshperspect.a006254.
Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(10):a006296. doi: 10.1101/ cshperspect.a006296.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-8. doi: 10.1038/33416.
Liscic RM, Breljak D. Molecular basis of amyotrophic lateral sclerosis. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):370-2. doi: 10.1016/j.pnpbp.2010.07.017.
Singleton A, Myers A, Hardy J. The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. Hum Mol Genet. 2004;13 Spec No 1:R123-6. doi: 10.1093/hmg/ ddh093.
Conlon EG, Manley JL. RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev. 2017;31(15):1509-28. doi: 10.1101/gad.304055.117.
Yeo G, Holste D, Kreiman G, Burge CB. Variation in alternative splicing across human tissues. Genome Biol. 2004;5(10):R74. doi: 10.1186/gb-2004-5-10-r74.
Grabowski PJ, Black DL. Alternative RNA splicing in the nervous system. Prog Neurobiol. 2001;65(3):289-308. doi: 10.1016/s0301-0082(01)00007-7.
Guthertz N, van der Kant R, Martinez RM, Xu Y, Trinh C, Iorga BI, et al. The effect of mutation on an aggregation-prone protein: an in vivo, in vitro, and in silico analysis. Proc Natl Acad Sci U S A. 2022;119(22):e2200468119. doi: 10.1073/ pnas.2200468119.
Stroo E, Koopman M, Nollen EA, Mata-Cabana A. Cellular regulation of amyloid formation in aging and disease. Front Neurosci. 2017;11:64. doi: 10.3389/fnins.2017.00064.
Venda LL, Cragg SJ, Buchman VL, Wade-Martins R. α-Synuclein and dopamine at the crossroads of Parkinson’s disease. Trends Neurosci. 2010;33(12):559-68. doi: 10.1016/j.tins.2010.09.004.
Chang E, Kim S, Yin H, Nagaraja HN, Kuret J. Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps. J Neurochem. 2008;107(4):1113-23. doi: 10.1111/j.1471- 4159.2008.05692.x.
Schaffert LN, Carter WG. Do post-translational modifications influence protein aggregation in neurodegenerative diseases: a systematic review. Brain Sci. 2020;10(4):232. doi: 10.3390/ brainsci10040232.
Gouras GK, Olsson TT, Hansson O. β-Amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics. 2015;12(1):3-11. doi: 10.1007/s13311-014-0313-y.
Alonso AD, Cohen LS, Corbo C, Morozova V, ElIdrissi A, Phillips G, et al. Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability. Front Cell Neurosci. 2018;12:338. doi: 10.3389/fncel.2018.00338.
Brothers HM, Gosztyla ML, Robinson SR. The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci. 2018;10:118. doi: 10.3389/fnagi.2018.00118.
Morley JE, Farr SA, Nguyen AD, Xu F. What is the physiological function of amyloid-beta protein? J Nutr Health Aging. 2019;23(3):225-6. doi: 10.1007/s12603-019-1162-5.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59. doi: 10.1007/bf00308809.
Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;9(7):a028035. doi: 10.1101/cshperspect.a028035.
Tutar Y, Özgür A, Tutar L. Role of protein aggregation in neurodegenerative diseases. In: Kishore U, ed. Neurodegenerative Diseases. Rijeka, Croatia: IntechOpen; 2013. p. 55-76.
Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252. doi: 10.1038/ncomms1255.
Singh A. Oscillatory activity in the cortico-basal ganglia-thalamic neural circuits in Parkinson’s disease. Eur J Neurosci. 2018;48(8):2869-78. doi: 10.1111/ejn.13853.
Asaadi S, Hojjati M, Zali A, Ashrafi F. Effect of HU-308 in mice models of Parkinson’s disease. J Neurol Sci. 2013;333(Suppl 1):e65. doi: 10.1016/j.jns.2013.07.505.
Choong CJ, Mochizuki H. Neuropathology of α-synuclein in Parkinson’s disease. Neuropathology. 2022;42(2):93-103. doi: 10.1111/neup.12812.
Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006;112(3):237-51. doi: 10.1007/s00401-006-0104-6.
Erskine D, Patterson L, Alexandris A, Hanson PS, McKeith IG, Attems J, et al. Regional levels of physiological α-synuclein are directly associated with Lewy body pathology. Acta Neuropathol. 2018;135(1):153-4. doi: 10.1007/s00401-017- 1787-6.
Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281(40):29739-52. doi: 10.1074/jbc.M600933200.
Zheng W, Zhang Z, Ye Y, Wu Q, Liu M, Li C. Phosphorylation dependent α-synuclein degradation monitored by in-cell NMR. Chem Commun (Camb). 2019;55(75):11215-8. doi: 10.1039/c9cc05662a.
Gómez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hyman BT. alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. 2000;99(4):352-7. doi: 0.1007/s004010051135.
Puschmann A, Englund E, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, et al. First neuropathological description of a patient with Parkinson’s disease and LRRK2 p.N1437H mutation. Parkinsonism Relat Disord. 2012;18(4):332-8. doi: 10.1016/j.parkreldis.2011.11.019.
Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, et al. Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem. 2008;283(6):3316-28. doi: 10.1074/jbc.M704809200.
Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson’s disease pathogenesis and therapies. Prog Brain Res. 2010;183:115-45. doi: 10.1016/s0079-6123(10)83007-9.
Nonaka T, Iwatsubo T, Hasegawa M. Ubiquitination of alpha-synuclein. Biochemistry. 2005;44(1):361-8. doi: 10.1021/ bi0485528.
Saha RN, Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 2006;13(4):539-50. doi: 10.1038/sj.cdd.4401769.
Shukla S, Tekwani BL. Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation. Front Pharmacol. 2020;11:537. doi: 10.3389/ fphar.2020.00537.
Öhrfelt A, Zetterberg H, Andersson K, Persson R, Secic D, Brinkmalm G, et al. Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. Neurochem Res. 2011;36(11):2029- 42. doi: 10.1007/s11064-011-0527-x.
Iyer A, Roeters SJ, Schilderink N, Hommersom B, Heeren RM, Woutersen S, et al. The impact of N-terminal acetylation of α-synuclein on phospholipid membrane binding and fibril structure. J Biol Chem. 2016;291(40):21110-22. doi: 10.1074/ jbc.M116.726612.
Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323-55. doi: 10.1146/annurev-biochem-060208-092442.
Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci. 2005;62(6):670- 84. doi: 10.1007/s00018-004-4464-6.
Chittoor-Vinod VG, Lee S, Judge SM, Notterpek L. Inducible HSP70 is critical in preventing the aggregation and enhancing the processing of PMP22. ASN Neuro. 2015;7(1):1759091415569909. doi: 10.1177/1759091415569909.
Falsone A, Falsone SF. Legal but lethal: functional protein aggregation at the verge of toxicity. Front Cell Neurosci. 2015;9:45. doi: 10.3389/fncel.2015.00045.
Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289(1-2):1-30. doi: 10.1016/j.ijpharm.2004.11.014.
- Abstract Viewed: 120 times
- PDF Downloaded: 175 times